Long-term therapeutic effect of new triple antiplatelet therapy on patients with ACS complicated diabe-tes mellitus after drug-eluting stenting
10.3969/j.issn.1008-0074.2018.03.22
- VernacularTitle:ACS合并糖尿病患者药物涂层支架术后应用新型三联抗血小板治疗的长期疗效
- Author:
Jian-Bin YIN
1
Author Information
1. 柳州市人民医院心内科
- Keywords:
Acute coronary syndrome;
Diabetes mellitus;
Angioplasty,balloon,coronary
- From:
Chinese Journal of cardiovascular Rehabilitation Medicine
2018;27(3):322-326
- CountryChina
- Language:Chinese
-
Abstract:
Objective :To explore long-term therapeutic effect of new triple antiplatelet therapy on patients with acute coronary syndrome (ACS) complicated diabetes mellitus (DM) after drug-eluting stenting .Methods :Data of 245 ACS + DM patients who received percutaneous coronary intervention in our hospital were collected .According postoperative therapeutic plan ,they were divided into dual antiplatelet group (n＝124 ,received aspirin combined clopidogrel) and triple antiplatelet group (n＝ 121 ,received aspirin ,clopidogrel combined cilostazol).Long-term therapeutic effect was compared between two groups after one year .Results :After one year ,incidence rate of ma-jor adverse cardiovascular events in triple antiplatelet group was significantly lower than that of dual antiplatelet group (8.3% vs.17.7%,P＝0.028).There were no significant difference in incidence rates of in-stent restenosis and adverse reactions between two groups (P＞ 0.05 both) ,and no severe hemorrhage events were found in two groups.Conclusion : Triple antiplatelet therapy of aspirin ,clopidogrel and cilostazol can significantly reduce inci-dence rate of MACE in ACS + DM patients after drug-eluting stenting .Compared with dual antiplatelet therapy of aspirin and clopidogrel ,it doesn't increase incidence rate of adverse drug reactions ,which is worth extending .
